RedHill Biopharma Культура компании

Mr. Dror Ben-Asher Co-Founded RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC. He has been affiliated with The Mercator Group since 1999. Mr. Ben-Asher has worked with Mercator on several projects including EquipNet, eCapitaledge.com, Tefron, Ltd. and Internet Media Group. He has extensive managerial and transactional expertise, He was with ProSeed Capital, a European corporate finance boutique. He was a Co-Founder of ProSeed Capital Holdings CVA and served as its President and Chief Executive Officer. He served as a Manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA from January 2002 to November 2010. He was a Co-Founder of ProSeed Venture I, L.P., and served as its President and Co-Chief Executive Officer. He served as a Consultant for a leading Israeli law firm and the Harvard International Law Journal at Harvard Law School. He served as an Officer in the Israeli Defence Forces. Mr. Ben-Asher has been the Chairman of RedHill Biopharma Ltd. since May 4, 2011 and has been its director since August 3, 2009. He serves as a Director of Agrea Ltd. He served as Director of ProSeed Venture I, L.P. He is writing his doctoral thesis at Harvard Law School. He concentrates on the pharmaceutical and medical devices industries and antitrust issues. He has a number of publications and teaches sections of graduates at Harvard Law School and undergraduates at Harvard's Economics department. At Harvard, he was a Fulbright Scholar focusing on the pharmaceutical industry and markets. He speaks fluent Hebrew and English and has some knowledge of Spanish. He is an Olin Fellow for Law, Economics and Business and an Economics Teaching Fellow at Harvard. He received his LL.B. with distinction (First Class Honours) from the University of Leicester. He is a graduate of the University of Oxford (M.Jur.). As an Oxford scholar, he received a Masters degree in European and Comparative Law from Oxford University, specializing in European business law, intellectual property and competition law. Mr. Ben-Asher completed LLM studies at Harvard University in the U.S.

Dr. Reza Fathi, Ph.D., has been Senior Vice President of Research & Development at RedHill Biopharma Ltd. since May 1, 2010. Dr. Fathi serves as Biotech Analyst at ProSeed Capital Holdings CVA and ProSeed Venture I, L.P. Prior to joining RedHill, he served as Director of Research Operations at XTL Biopharmaceuticals Inc. from 2005 to 2009. He is an expert in pharmaceutical research and development with 20 years of experience in medicinal chemistry, designing experimental protocols and managing research teams. He worked at PhytoMedical Technologies, Inc. He was Chemistry Core Manager at Harvard Medical School's Harvard Institute of Chemistry and Cell Biology. From 1998 to 2000, he served as Manager of Chemical Biology Research at the Institute of Chemistry and Chemical Biology (ICCB) at Harvard Medical School, pioneering chemical genetics to identify small molecules in cancer biology. From 1991 to 1998, he headed the Discovery Group at PharmaGenics, Inc. He was a Senior Scientist in the organic laboratory of Metrigen, NJ from 1990 to 1991. He worked at Enzo Biochem. From 2000 to 2005, Dr. Fathi served as Director of Research Operations at Vivoquest, Inc., responsible for developing a number of novel natural product based combinatorial technologies for infectious diseases such as HCV and HIV. Dr. Fathi has been a Member of Advisory Board at Cypak AB. He served as a Member of Scientific Advisory Board at Ceres Ventures, Inc. since April 2008. He was a Member of the Scientific Advisory Committee for Proseed Capital Holding CVA. He has published extensively and presented his papers on numerous occasions. He is first author of numerous patents and more than a dozen scientific publications in subjects including small molecule drug discovery, lead compound identification and synthesis of natural product based molecular libraries. Dr. Fathi received his Bachelor of Science (Chemistry) from Texas Tech University (1981), was a Graduate Research Assistant at the Chemistry Department of Rutgers State University, NJ (1987), and also holds a Post-Doctoral Fellow in Chemistry and Ph.D. in Organic Chemistry from Rutgers University, NJ, U.S.

Mr. Micha Ben-Chorin has been the Chief Financial Officer at RedHill Biopharma Ltd. since March 1, 2016. Mr. Ben-Chorin served as the Chief Financial Officer of Starhome GmbH. Mr. Ben-Chorin joined Starhome in March 2009 and has a wealth of experience and knowledge in managing a global finance operation. Mr. Ben-Chorin served as the Chief Financial Officer of WiNetworks, Inc., since 2006 and also served as its Executive Vice President. Mr. Ben-Chorin served for three years as Global Village Telecom (GVT) Corporate Controller in the USA and also served as the Chief Financial Officer of GVT in Brazil, where he was instrumental in positioning the GVT into the most successful new entrant to the Brazilian telecom market on the edge of a billion dollar IPO. Mr. Ben-Chorin served as the Chief Financial Officer and Executive Vice President of Interlogic Ltd., a leading online skill gaming company, where he lead the IPO processes in both the London Stock Exchange and the Tel Aviv Stock Exchange. Mr. Ben Chorin has over 20 years of financial management experience with specific expertise in financing, M&A and international operations. Mr. Ben-Chorin is a Certified Public Accountant. He holds a B.A in Economics & Accounting from the Tel-Aviv University and a Master's Degree in Eastern Asian philosophy studies from Tel Aviv University.

Mr. Guy Goldberg, J.D., has been the Chief Business Officer of RedHill Biopharma Ltd. since July 16, 2012. Mr. Goldberg served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey and also served as its Vice President from July 2007 to July 2012. Previously, he was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. He was an Associate at ProQuest Investments from 2004 to 2007. He was employed at Acurian and Guava Technologies. He was a consultant at McKinsey & Company from 2002 to 2004. He held positions at McKinsey and Company, where he developed strategic recommendations for a variety of Fortune 500 companies. Mr. Goldberg holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School in the U.S.

Mr. Gilead Raday, MPhil, MSc, has been the Chief Operating Officer at RedHill Biopharma Ltd. since April 22, 2016. Mr. Raday is a principal of CSS Capital Managers LLP, or CSS, an affiliate of Charles Street Securities Europe LLP, or CSS Europe. He partly owns manages the Bio-Pharma financing practice of CSS Europe in Israel. He served as Senior Vice President of Corporate & Product Development at RedHill Biopharma Ltd. from December 5, 2012 to April 22, 2016. He served as Vice President of Corporate and Product Development at RedHill Biopharma Ltd. from November 2010 to December 2012. From January 2010 to October 2010, he served as an Interim Chief Executive Officer of Sepal Pharma Plc. He was an Independent Consultant, specializing in business development and project management in the field of life sciences from January 2009 to December 2009. From 2004 to 2008, Mr. Raday served as a Partner at Charles Street Securities Europe, LLP and also served as its Managing Director of Life Sciences. Prior to CSS, he was employed in the Israel Air Force as a fighter pilot, ranked major. He serves as a Director of Sepal Pharma Plc and ViDAC Limited. He served as Non-Executive Director of Vaccine Research International Plc. Mr. Raday served as Director of Celsus Therapeutics Plc since June 16, 2005. He served as Director of TKsignal Plc and Morria Biopharmaceuticals Plc. He served as Director of Miras Medical Imaging Plc. He is a graduate of the University of Cambridge (MPhil in Biotechnology Management/Bioscience enterprise, 2004) and the Hebrew University of Jerusalem (MSc Neurobiology 2007 and BSc Mathematics & Biology).

Valerie Graceffa serves as the Vice President Sales and Marketing of RedHill Biopharma Ltd.. Valerie started at RedHill Biopharma Ltd. in May of 2017. Valerie currently resides in the Raleigh-Durham, North Carolina Area.

Danielle Abramson serves as the Vice President, Intellectual Property & Research of RedHill Biopharma Ltd.. Danielle currently resides in the Greater New York City Area.

Craig Miller serves as the Vice President, US Business Operations, Market Access of RedHill Biopharma Ltd.. Craig currently resides in the Raleigh-Durham, North Carolina Area.

Shani Maurice serves as the VP Business Development & Communications of RedHill Biopharma Ltd.. Shani currently resides in the Greater Chicago Area.